There is a report that blocking TGF-β along with immune checkpoint therapy increases Th1 subsets and promotes clonal expansion of CD8 T cells, thereby leading to the regression of bone castration-resistant prostate cancer and improved survival (42). Here, CD8A is linked to prostate cancer.